期刊： CLINICS IN CHEST MEDICINE, 2023; 44 (2)
COVID-19 often results in more severe infections in immunocompromised patients. Hospitalization rate, disease severity, and mortality rates are genera......
期刊： CLINICS IN CHEST MEDICINE, 2023; 44 (4)
Rates of nontuberculous mycobacterial pulmonary disease are increasing worldwide, particularly in the United States and other developed countries. Whi......
期刊： CLINICS IN CHEST MEDICINE, 2023; 44 (4)
Most patients who are treated for NTM-PD will experience a treatment related adverse event. Adverse effects are the most frequently cited reason for a......
